{
  "source": "PA-Notification-Votrient.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1113-13\nProgram Prior Authorization/Notification\nMedication Votrient® (pazopanib)\nP&T Approval Date 1/12/2010, 9/2010, 12/2010, 3/2011, 5/2012, 8/2012, 7/2013, 8/2014,\n8/2015, 7/2016, 7/2017, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,\n11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nVotrient (pazopanib) is a kinase inhibitor indicated for the treatment of adults with advanced\nrenal cell carcinoma and advanced soft tissue sarcoma in patients who have received prior\nchemotherapy. Additionally, the National Comprehensive Cancer Network (NCCN) recommends\nuse of Votrient in treatment of medullary, follicular, oncocytic, and papillary thyroid carcinomas;\novarian cancer; additional soft tissue sarcomas, chondrosarcoma, uterine sarcoma, merkel cell\ncarcinoma, and gastrointestinal stromal tumors (GIST).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Votrient will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Renal cell carcinoma (RCC)/Kidney cancer\n1. Initial Authorization\na. Votrient will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of renal cell carcinoma (RCC)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(b) One of the following:\ni. Disease has relapsed\nii. Stage IV disease\niii. Disease is advanced\n-OR-\n(2) Diagnosis of von Hippel-Lindau (VHL)-associa",
    "CC)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(b) One of the following:\ni. Disease has relapsed\nii. Stage IV disease\niii. Disease is advanced\n-OR-\n(2) Diagnosis of von Hippel-Lindau (VHL)-associated renal cell carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nC. Soft Tissue Sarcoma (STS)\n1. Initial Authorization\na. Votrient will be approved based on the following criterion:\n(1) Diagnosis of one of the following:\n(a) Angiosarcoma\n(b) Alveolar soft part sarcoma\n(c) Pleomorphic rhabdomyosarcoma\n(d) Retroperitoneal/Intra-abdominal disease that is unresectable, stage IV, or\npostoperative treatment for residual disease\n(e) Soft Tissue Sarcoma of the Extremity/Superficial Trunk or Head/Neck with\ndisease that is stage IV or recurrent and has disseminated metastases\n(f) Solitary fibrous tumor/hemangiopericytoma\n(g) Desmoid tumors (aggressive fibromatosis)\n(h) Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous\nTransformation\n(i) Dedifferentiated Chordoma\n(j) Epithelioid hemangioendothelioma\n(k) Extraskeletal myxoid chondrosarcoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\nD. Thyroid Carcinoma\n1. Initial Authorization\na. Votrient will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of one of the following:\ni. Follicular carcinoma\nii. Oncocytic carcinoma\niii. Papillary carcinoma\n-AND-\n(b) One of the following:\ni. Unresectable locoregional recurrent disease\nii. Persistent disease\niii. Metastatic disease\n-AND-\n(c) One of the following:\ni. Patient has symptomatic di",
    "ry carcinoma\n-AND-\n(b) One of the following:\ni. Unresectable locoregional recurrent disease\nii. Persistent disease\niii. Metastatic disease\n-AND-\n(c) One of the following:\ni. Patient has symptomatic disease\nii. Patient has progressive disease\n-AND-\n(d) One of the following:\ni. Disease is refractory to radioactive iodine treatment\nii. Distant metastatic disease not amenable to radioactive iodine\ntreatment\n-OR-\n(2) All of the following:\n(a) Diagnosis of medullary carcinoma\n-AND-\n(b) One of the following:\n© 2024 UnitedHealthcare Services, Inc.\n3\ni. Disease is progressive\nii. Disease is symptomatic with distant metastases\n-AND-\n(c) History of failure, contraindication, or intolerance to one of the\nfollowing:\ni. Caprelsa (vandetanib)\nii. Cometriq (cabozantinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nE. Uterine Sarcoma\n1. Initial Authorization\na. Votrient will be approved based on both of the following criteria:\n(1) Diagnosis of uterine sarcoma\n-AND-\n(2) One of the following:\n(a) Disease is advanced\n(b) Disease is recurrent/metastatic\n(c) Disease is inoperable\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nF. Ovarian Cancer\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n4\na. Votrient will be approved based on all of the following criteria:\n(1) Diagnosis of one of the following:\n(a) Epithelial Ovarian Cancer\n(b) Fallopian Tube Cancer\n(c) Primary Peritoneal Cancer\n-AND-\n(2) One of the following:\n(a) Disease is persistent\n(b) Disease is recurrent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on",
    "eritoneal Cancer\n-AND-\n(2) One of the following:\n(a) Disease is persistent\n(b) Disease is recurrent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nG. Chondrosarcoma\n1. Initial Authorization\na. Votrient will be approved based on both of the following criteria:\n(1) Diagnosis of chondrosarcoma\n-AND-\n(2) Disease is metastatic and widespread\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nH. Gastrointestinal Stromal Tumors (GIST)\n© 2024 UnitedHealthcare Services, Inc.\n5\n1. Initial Authorization\na. Votrient will be approved based on all the following criteria:\n(1) Diagnosis of GIST\n-AND-\n(2) Disease is unresectable, progressive, or metastatic\n-AND-\n(3) One of the following:\n(a) Used as first-line therapy in SDH-deficient GIST\n-OR-\n(b) Used after progression on all of the following:\ni. Gleevec (imatinib)\nii. Sutent (sunitinib)\niii. Stivarga (regorafenib)\niv. standard dose Qinlock (ripretinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nI. Merkel Cell Carcinoma\n1. Initial Authorization\na. Votrient will be approved based on all of the following criteria:\n(1) Diagnosis of Merkel Cell Carcinoma\n-AND-\n(2) Disease is M1 disseminated\n-AND-\n(3) One of the following:\n© 2024 UnitedHealthcare Services, Inc.\n6\n(a) Anti-PD-L1 or anti-PD-1 therapy is contraindicated\n-OR-\n(b) Disease has progressed on anti-PD-L1 or anti-PD-1 therapy\nAuthorization will be issued for 12 months.\n",
    "UnitedHealthcare Services, Inc.\n6\n(a) Anti-PD-L1 or anti-PD-1 therapy is contraindicated\n-OR-\n(b) Disease has progressed on anti-PD-L1 or anti-PD-1 therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Votrient will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Votrient therapy\nAuthorization will be issued for 12 months.\nJ. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nJanuary 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed October 9, 2024.\nProgram Prior Authorization/Notification - Votrient (pazopanib)\nChange Control\n8/2014 Annual review. Expanded disease description for RCC and reformatted\nthyroid carcinoma. Updated Background and References.\n8/2015 Annual review. Updated criteria for soft tissue cancer and thyroid\n© 2024 UnitedHealthcare Services, Inc.\n7\ncancer. Added criteria for dermatofibrosarcoma protuberans and\novarian cancer. Updated background and references.\n7/2016 Annual review. Revised renal cell carcinoma and soft tissue sarcoma\ncriteri",
    ".\n7\ncancer. Added criteria for dermatofibrosarcoma protuberans and\novarian cancer. Updated background and references.\n7/2016 Annual review. Revised renal cell carcinoma and soft tissue sarcoma\ncriteria. Updated references.\n7/2017 Annual review with no changes to coverage criteria. Updated\nreferences.\n11/2017 Updated criteria to align with NCCN recommendations for recurrent or\npersistent ovarian cancer. Removed criteria for dermatofibrosarcoma\nprotuberans (DFSP) as no longer recommended by NCCN. Updated\nreference.\n11/2018 Annual review. Updated criteria to align with NCCN recommendations\nfor renal cell carcinoma. Removed “off-label” from NCCN\nCompendium supported indications. Updated background and\nreferences.\n11/2019 Annual review. Updated criteria to align with NCCN recommendations\nfor soft tissue sarcomas, ovarian and uterine cancers. Added NCCN\nrecommended regimens criteria. Updated background and references.\n11/2020 Annual review. Updated criteria to align with NCCN recommendations\nfor soft tissue sarcoma and thyroid carcinoma. Updated background and\nreferences.\n11/2021 Annual review. Updated criteria to align with NCCN recommendations\nfor soft tissue sarcoma. Added criteria for chondrosarcoma. Updated\nbackground and references.\n11/2022 Annual review. Added state mandate and updated references.\n11/2023 Annual review. Moved and updated criteria for GIST into its own\nsection. Added Merkel Cell Carcinoma criteria per NCCN\nrecommendations. Updated Soft Tissue Sarcoma criteria to align with\nNCCN. Updated Uterine Sarcoma criteria to align with NCCN.\nUpdated Hürthle cell to oncocytic to align with NCCN nomenclature.\nUpdated background to align with NCCN recommendations. Updated\nreference.\n11/2024 Annual review. Added epithelioid hemangioendothelioma and\nextraskeletal myxoid chondrosarcoma to Soft Tissue Sarcoma criteria to\nalign with NCCN. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n8"
  ]
}